| To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years (NCT06756269) | Shanghai Bovax Biotechnology Co., Ltd. | 2025-01-15 |
| A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years (NCT06454175) | Shanghai Bovax Biotechnology Co., Ltd. | 2024-08-03 |
| A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males (NCT06465914) | Shanghai Bovax Biotechnology Co., Ltd. | 2024-07-11 |
| A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females (NCT05584332) | Shanghai Bovax Biotechnology Co., Ltd. | 2022-12-09 |
| Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old (NCT05518201) | Shanghai Bovax Biotechnology Co., Ltd. | 2022-09-23 |
| Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine (NCT05371353) | Shanghai Bovax Biotechnology Co., Ltd. | 2022-05-14 |
| Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years (NCT05027776) | Shanghai Bovax Biotechnology Co., Ltd. | 2021-09-15 |
| Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years (NCT04895020) | Shanghai Bovax Biotechnology Co., Ltd. | 2021-05-28 |
| Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (NCT05372016) | Shanghai Bovax Biotechnology Co., Ltd. | 2020-09-19 |
| Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (NCT04425291) | Shanghai Bovax Biotechnology Co., Ltd. | 2020-05-28 |
| Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (NCT04422366) | Shanghai Bovax Biotechnology Co., Ltd. | 2020-04-28 |
| Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females (NCT03676101) | Shanghai Bovax Biotechnology Co., Ltd. | 2018-10-10 |